✦ LIBER ✦

Tumor Lysis Syndrome Occurring After the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder

✍ Scribed by S.A. Francescone; B. Murphy; J.T. Fallon; K. Hammond; S. Pinney

Book ID: 116935258
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 990 KB
Volume: 41
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2009.03.060

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tumor lysis syndrome occurring after the

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

✍ Yang, Honghao; Rosove, Michael H.; Figlin, Robert A. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB 👁 2 views

Rituximab, an anti-CD20 antibody, has been recently approved for the treatment of lowgrade or follicular non-Hodgkin's lymphoma (NHL). Because of its relatively benign side effect profile, it has been considered a nontoxic alternative to chemotherapy. Recently, however, tumor lysis syndrome (TLS) re

Rituximab treatment for posttransplant l

Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome

✍ Kandai Nozu; Kazumoto Iijima; Masato Fujisawa; Atsuko Nakagawa; Norishige Yoshik 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 182 KB

Rituximab therapy is effective for postt

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation : Results of a phase II trial

✍ Anne H. Blaes; Bruce A. Peterson; Nancy Bartlett; David L. Dunn; Vicki A. Morris 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

The emergence of CD20−/CD19− tumor cells

The emergence of CD20−/CD19− tumor cells after rituximab therapy for Epstein–Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis

✍ Yamamoto, Nobuyuki; Nishimura, Noriyuki; Takeuchi, Mai; Ito, Tomoo; Yokozaki, Hi 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 387 KB

Rituximab (anti-CD20 monoclonal antibody

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases

✍ Simona Zompi; Micheline Tulliez; Filoména Conti; Véronique Leblond; Philippe Gau 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 1013 KB